source
- Administrative gap stalls access to new pancreatic cancer therapyA recent Morning Rounds report notes that patients awaiting a new pancreatic cancer treatment are encountering delays because an administrative gap has halted its rollout. The story explains that…
- Beyond GLP-1s: Companies eye new obesity drug mechanisms as efficacy plateausThe obesity drug market continues to expand, with GLP-1 therapies growing from about $5.5 billion in 2023 to over $55 billion projected for 2033. These agents are used for weight loss, diabetes and…